Application of tanshinone I in preparation of medicine for treating psoriasis

A technology for tanshinone and psoriasis is applied in the application field of tanshinone I in the preparation of medicines for the treatment of psoriasis, which can solve the problems of large toxic and side effects, intolerance of patients, expensive biological preparations and the like, and achieves strong development prospects and safety. Good sex, significant effect

Inactive Publication Date: 2013-03-27
GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The etiology and pathogenesis of psoriasis are very complicated. At present, the drugs for the treatment of psoriasis include tretinoin, methotrexate, cyclosporine, etanercept or dexamethasone, etc., but these drugs have many shortcomings : If the side effects are large, many patients cannot tolerate it; it can only quickly control the symptoms of patients in the ongoing stage, but cannot effectively prolong the remission period of patients; biological agents such as etanercept are very expensive
[0007] According to current literature reports, the tanshinone I can dilate blood vessels, improve circulation, increase blood flow, and simultaneously have various pharmacological effects such as calming the nerves, lowering blood pressure, lowering blood sugar, anti-inflammation, anti-allergy, and anti-oxidation. Related reports of Tanshinone I used in the treatment of psoriasis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tanshinone I in preparation of medicine for treating psoriasis
  • Application of tanshinone I in preparation of medicine for treating psoriasis
  • Application of tanshinone I in preparation of medicine for treating psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Prepare oral Tanshinone I capsules (1000 capsules) for the treatment of psoriasis. The weight of the components is as follows:

[0017]

[0018] Production process: Mix Tanshinone I and lactose evenly, moisten it with water, then pass through a 20-mesh sieve, dry, and again pass through a 22-mesh sieve, then add magnesium stearate, mix well, and fill the capsule.

Embodiment 2

[0020] To prepare the tanshinone I cream for external use in the treatment of psoriasis, the weight percentages of the components are as follows:

[0021]

[0022]

[0023] Production Process:

[0024] 1. Weigh all the components of phase A and mix at 90℃;

[0025] 2. Weigh all the components of phase B and mix them at 90℃;

[0026] 3. Slowly add phase A to phase B, stirring while adding, for about 20 minutes;

[0027] 4. After homogenizing for 20 minutes, cool to room temperature to obtain the cream.

Embodiment 3

[0029] Experimental research report of Tanshinone I inhibiting the proliferation of human keratinocytes (HaCaT cells):

[0030] 1. Materials and methods

[0031] 1.1 Material Tanshinone I standard product was purchased from the National Institute for the Control of Pharmaceutical and Biological Products; the positive control drug anthranol was purchased from Wuhan Tongxing Biotechnology Company; 3-(4,5-dimethylthiazole-2)-2,5-two Phenyltetrazolium bromide (MTT) was purchased from Beijing Dingguo Biotechnology Co., Ltd.; Hoechest 33258 fluorescent dye was purchased from sigma, USA; Annexin V cell apoptosis detection kit was purchased from Lianke Biotechnology Co., Ltd.

[0032] 1.2 Instruments BX-61 fluorescence microscope from Olympus, Japan; FC-500 flow cytometer from Beckman Coulter, USA; Epoch microplate reader from BIOTEK, USA.

[0033] 1.3 method

[0034] 1.3.1 MTT detects cell proliferation and IC 50 Calculation

[0035] Choose logarithmic growth phase HaCaT cells, digest with dig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of tanshinone I in preparation of a medicine for treating psoriasis. The medicine comprises therapeutically effective amount of tanshinone I and medically acceptable vectors, wherein the content of tanshinone I is 1-99wt%. The tanshinone I can be prepared into clinically or medically acceptable preparations, including commonly-used oral solid preparations such as capsules and tablets, or external preparations such as emulsifiable paste or cream and gels; the preparations can be applied to a patient needing treatment in external use and oral ways; and the tanshinone I has an obvious effect of inhibiting HaCaT cell proliferation, and can be applied to preparation of the medicine for treating psoriasis. The medicine prepared by the tanshinone I has the beneficial effects that the remarkable effects are verified in animal experiments and clinical tests, and the safety is high; and the medicine is a novel medicine for treating the psoriasis, and has a good development prospect.

Description

Technical field [0001] The invention relates to a new use of tanshinone I, in particular to the application of tanshinone I in preparing medicines for treating psoriasis. Background technique [0002] Psoriasis is one of the common refractory skin diseases. It is mainly manifested by the excessive proliferation of keratinocytes, the aggregation of inflammatory cells, and the proliferation and expansion of blood vessels in the dermal papilla, resulting in hyperkeratosis, incomplete keratosis, disappearance of the granular layer, and spine Clinicopathological changes such as cell layer thickening. (Frank O. Nestle, Daniel H. Kaplan, Jonathan Barker. Psoriasis [J]. N EnglJ Med, 2009, 361:496-509). The clinical classification of psoriasis mainly includes vulgaris, pustular, charcoal, and erythroderma. Psoriasis is a high-incidence species, especially affecting young adults, so it has a great impact on the patient's body and mind. (Weger W. Current status and new developments in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/58A61P17/06
Inventor 卢传坚贺嵩敏朱伟
Owner GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products